Sinomex Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 1.75 Cr
as on 21-12-2024
- Paid Up Capital ₹ 0.29 M
as on 21-12-2024
- Company Age 3 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.63 Cr
as on 21-12-2024
About Sinomex Diagnostics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.75 Cr and a paid-up capital of Rs 0.29 M.
The company currently has active open charges totaling ₹10.63 Cr.
Mayank Gola and Dharam Singh serve as directors at the Company.
- CIN/LLPIN
U33100DL2021PTC389589
- Company No.
389589
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Nov 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sinomex Diagnostics Private Limited offer?
Sinomex Diagnostics Private Limited offers a wide range of products and services, including Infusion Syringes & Supplies, Catheter, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Surgical & ICU Equipments, Dialysis Machine, Medical Surgery & Treatment Centres, Medical Treatment Services, Disposable Cannulas, Forceps & Graspers.
Who are the key members and board of directors at Sinomex Diagnostics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mayank Gola  | Director | 09-Nov-2021 | Current |
| Dharam Singh | Additional Director | 26-Mar-2024 | Current |
Financial Performance of Sinomex Diagnostics.
Sinomex Diagnostics Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Sinomex Diagnostics?
In 2022, Sinomex Diagnostics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Nov 2024 | ₹2.92 M | Open |
Others Creation Date: 28 Oct 2024 | ₹2.70 M | Open |
Bank Of India Creation Date: 13 May 2024 | ₹10.00 Cr | Open |
How Many Employees Work at Sinomex Diagnostics?
Sinomex Diagnostics has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sinomex Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sinomex Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
